

APPLICANT FACSIMILE OF FORM PTO-1449

REV 7-80

U.S. DEPARTMENT OF  
COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO

GNN-016

SERIAL NO.

09/805,801

LIST OF PUBLICATIONS CITED BY APPLICANT  
(Use several sheets if necessary)

APPLICANT

Mary Collins et al.

FILING DATE

March 13, 2001

GROUP

1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RG	A1	5,747,034	5/98	de Boer et al.	424	137.1	
	A2	5,869,050	2/99	de Boer et al.	424	156.1	
	A3	6,015,809	1/00	Zhu et al.	514	210	
	A4	5,885,579	3/99	Linsley et al.	424	192.1	
	A5	5,942,607	8/99	Freeman et al.	536	23.5	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A6	WO 95/16691 A1	6/95	PCT				
	A7	WO 95/34320 A2,A3	12/95	PCT				
	A8	WO 96/40915 A2,A3	12/96	PCT				
	A9	WO 95/03408 A1	2/95	PCT				
	A10	WO 98/58965 A2,A3	12/98	PCT				
	A11	WO 00/47625 A2	8/00	PCT				

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	A12	Azuma M, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993 Nov 4;366(6450):76-9
	A13	Bashuda H, et al. Specific acceptance of cardiac allografts after treatment with antibodies to CD80 and CD86 in mice. Transplant Proc. 1996 Apr;28(2):1039-41
	A14	Blazar B, et al. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells. The Journal of Immunology, 1996 Oct 15, 157(8):3250-3259
	A15	Bree A, et al. Humanized anti-B7.1 and anti-B7.2 antibodies prevent antigen-specific induction of immunity in nonhuman primates immunized with tetanus toxoid and mumps virus vaccine. Nature. 1999 Nov 15, 94(10):439a
	A16	Damico, L.A. et al. Pharmacokinetics of IV Administered Murine Anti-Human B7.1 and Murine Anti-Human B7.2 In Cynomolgus Monkeys. Supplement to Transplantation 1998 May 9-13, 65: abstract number 379
RG	A17	Kirk AD, et al. Primate allotransplantation using costimulation blockade. Supplement to Transplantation 2000 April 27,69(8):S414 : abstract number 1156



Examiner

Philip Gamber 10/7/02

Date Considered

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO <b>GNN-016</b>	SERIAL NO. <b>09/805,801</b>
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT <b>Mary Collins et al.</b>	GROUP <b>1614 1644</b>
		FILING DATE <b>March 13, 2001</b>	



RECEIVED

APR 25 2002

TECH CENTER-1600/2900

APR 25 2002

RECEIVED

## OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

<i>PG</i>	B1		Kirk A et al. Long-term rejection-free survival in primate allotransplantation with costimulation blockade Transplantation 1999, APR 15 67(7) P2-2 Abstract 2;S7
	B2		Lenschow DJ, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science. 1992 Aug 7;257(5071):789-92
	B3		Li Y, et al. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation. 1998 Nov 27;66(10):1387-8
	B4		Opelz G. Effect of immunosuppressive therapy on graft half-life projections. The Collaborative Transplant Study. Transplant Proc. 1999 Nov;31(7A):31S-33S
	B5		Ossevoort MA et al. Blocking of costimulatory pathways using monoclonal antibodies as a new strategy to prevent transplant rejection in a non-human primate model. Transplant Prot. 1998 30:1061-1062
	B6		Ossevoort MA, et al. Blocking of costimulation prevents kidney graft rejection in rhesus monkeys. Transplant Proc. 1998 Aug;30(5):2165-6
	B7		Ossevoort MA, et al. Prevention of renal allograft rejection in primates by blocking the B7/CD28 pathway. Transplantation. 1999 Oct 15;68(7):1010-8
	B8		Rugtveit J, et al. Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD). Clin Exp Immunol. 1997 Oct;110(1):104-13
	B9		Turka LA, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):11102-5
	B10		He G, et al. The role of CD8 and CD4 T cells in intestinal allograft rejection: a comparison of monoclonal antibody-treated and knockout mice. Transplantation. 1999 Jan 15;67(1):131-7
<i>PG</i>	B11		Lenschow DJ, et al. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation. 1995 Nov 27;60(10):1171-8
Examiner <i>Phuup G. Tran 10/7/02</i>		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			